- Conditions
- Breast Cancer With Low to Intermediate HER2 Expression
- Interventions
- Echocardiogram
- Procedure
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years to 79 Years · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 1
- States / cities
- Rochester, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 344
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Cervical Cancer, Behavior
- Interventions
- Care Group Cervical Cancer Screening Education Curriculum
- Behavioral
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 30 Years to 59 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Ovarian Cancer, Epithelial, Peritoneal Cancer, Fallopian Tube Cancer
- Interventions
- Streamlined Education, Traditional Education
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC, SCC - Squamous Cell Carcinoma, SCCHN, Head Neck Cancer, Head and Neck Squamous Cell Cancer, Squamous Cell Carcinoma of the Head and Neck, Squamous Cell Carcinoma, Head And Neck, Squamous Cell Head and Neck Carcinoma, Oral Cavity, Oral Cavity Carcinoma
- Interventions
- VRP-encapsulated saRNA encoding IL-12 (1 x 10^9 viral particles per injection), Pembrolizumab (KEYTRUDA®), VRP-encapsulated saRNA encoding IL-12 (3 x 10^8 viral particles per injection)
- Biological · Drug
- Lead sponsor
- VLP Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Cancer Prevention, Cervix
- Interventions
- Cognitive Interview, Questionnaires, Focus Groups
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 188 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer
- Interventions
- Not listed
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Interventions
- human myeloid progenitor cells
- Biological
- Lead sponsor
- Cellerant Therapeutics
- Industry
- Eligibility
- 12 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2014
- U.S. locations
- 8
- States / cities
- Orange, California • Wilmington, Delaware • Washington D.C., District of Columbia + 5 more
- Conditions
- Breast Conserving Surgery, Mastectomy With Reconstruction
- Interventions
- BREAST-Q Physical Well-Being, QuickDASH
- Other
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 6
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Commack, New York + 3 more
- Conditions
- Cancer
- Interventions
- Wawokiya Health Advocate
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Rapid City, South Dakota
- Conditions
- Cancer
- Interventions
- Wearable
- Other
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Multiple Myeloma
- Interventions
- Bortezomib (Velcade), Panobinostat
- Drug
- Lead sponsor
- University of Arkansas
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- Little Rock, Arkansas
- Conditions
- Prostate Cancer
- Interventions
- Abemaciclib 200 MG, Atezolizumab 1200 MG in 20 ML Injection, Abemaciclib 150 MG
- Drug
- Lead sponsor
- University of Michigan Rogel Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • Minneapolis, Minnesota • St Louis, Missouri + 1 more
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Pediatric Cancer
- Interventions
- Multi-level communication intervention
- Behavioral
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Acute Leukemia, Lymphoblastic Leukemia, Lymphoblastic Lymphoma
- Interventions
- LP-118, Ponatinib, Vincristine, Dexamethasone, Methotrexate
- Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 2
- States / cities
- Chicago, Illinois • Rochester, New York
- Conditions
- Cancer, Thyroid
- Interventions
- Ultrasound, Shear wave elasticity imaging, Multi-angle compound shear wave elasticity imaging
- Diagnostic Test
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Breast Cancer
- Interventions
- trastuzumab emtansine
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 4
- States / cities
- Fort Myers, Florida • Detroit, Michigan • Portland, Oregon + 1 more
- Conditions
- Cancer, Gastrointestinal Cancer
- Interventions
- Pharmacogenomic Testing with the "Global Diversity Array with Enhanced PGx"
- Genetic
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- DYP688
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Hodgkin Lymphoma, Non-hodgkin Lymphoma, Lymphoma, Breast Cancer
- Interventions
- Physical Activity Intervention (PAI), Healthy Living Control
- Other
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 2
- States / cities
- Richmond, Virginia • South Hill, Virginia
- Conditions
- Prostate Cancer
- Interventions
- hyperpolarized pyruvate +/-urea (13C/15N), Non-investigational External beam radiotherapy (EBRT), Radiotherapy (RT), Multi-parametric magnetic resonance imaging (mpMRI), Non-interventional hormone therapy, Prostate Biopsy
- Drug · Radiation · Procedure + 1 more
- Lead sponsor
- Robert Bok, MD, PhD
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 161 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Breast Cancer, Corpus Uteri Cancer, Ovary Cancer, Pancreas Cancer, Other Female Genital Malignant Neoplasms
- Interventions
- INSPIRE (INtegrating Systematic PatIent-Reported Evaluations), Capture of patient-reported outcomes, Enhanced Clinician Awareness
- Behavioral
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,748 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 3
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oklahoma City, Oklahoma
- Conditions
- Prostate Cancer
- Interventions
- Degarelix
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2006
- U.S. locations
- 23
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Anchorage, Alaska + 19 more
- Conditions
- Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
- Interventions
- aldesleukin, cyclophosphamide, fludarabine phosphate, Individual Patient TCR-Transduced PBL, TruSight Oncology (TSO) 500
- Drug · Biological · Device
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland